This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
-
BioXcel Clinical Research Site 103, Chino, California, United States, 91710
BioXcel Clinical Research Site 105, Oceanside, California, United States, 92056
BioXcel Clinical Research Site 102, Orange, California, United States, 92868
BioXcel Clinical Research Site 101, Saint Louis, Missouri, United States, 63125
BioXcel Clinical Research Site 106, Las Vegas, Nevada, United States, 89119
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
No
BioXcel Therapeutics Inc,
Matt Mandel, MD, STUDY_CHAIR, BioXcel Therapeutics
2025-10